BNP Paribas Financial Markets’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-19,061
| Closed | -$115K | – | 4558 |
|
|
2019
Q4 | $115K | Sell |
19,061
-298,615
| -94% | -$1.73M | ﹤0.01% | 3228 |
|
|
2019
Q3 | $1.14M | Buy |
317,676
+299,615
| +1,659% | +$1.16M | ﹤0.01% | 1783 |
|
|
2019
Q2 | $48.4K | Sell |
18,061
-13,383
| -43% | -$39.5K | ﹤0.01% | 3436 |
|
|
2019
Q1 | $93.1K | Buy |
31,444
+28,404
| +934% | +$69.8K | ﹤0.01% | 3165 |
|
|
2018
Q4 | $4.83K | Sell |
3,040
-4,682
| -61% | -$13.2K | ﹤0.01% | 3600 |
|
|
2018
Q3 | $28.4K | Buy |
7,722
+595
| +8% | +$1.77K | ﹤0.01% | 3272 |
|
|
2018
Q2 | $20.2K | Sell |
7,127
-23,582
| -77% | -$80.3K | ﹤0.01% | 3496 |
|
|
2018
Q1 | $114K | Buy |
30,709
+4,883
| +19% | +$16K | ﹤0.01% | 3119 |
|
|
2017
Q4 | $74.4K | Buy |
25,826
+13,305
| +106% | +$48.3K | ﹤0.01% | 3463 |
|
|
2017
Q3 | $56.2K | Sell |
12,521
-3,920
| -24% | -$17.4K | ﹤0.01% | 3093 |
|
|
2017
Q2 | $75.5K | Buy |
16,441
+14,389
| +701% | +$57.8K | ﹤0.01% | 2968 |
|
|
2017
Q1 | $8.64K | Sell |
2,052
-6,092
| -75% | -$25.3K | ﹤0.01% | 3195 |
|
|
2016
Q4 | $33.6K | Sell |
8,144
-1,548
| -16% | -$8.23K | ﹤0.01% | 2995 |
|
|
2016
Q3 | $78.5K | Buy |
9,692
+5,137
| +113% | +$43.7K | ﹤0.01% | 2218 |
|
|
2016
Q2 | $35.5K | Buy |
+4,555
| New | +$39.1K | ﹤0.01% | 2406 |
|
|
2016
Q1 | – | Sell |
-25,324
| Closed | -$273K | – | 3303 |
|
|
2015
Q4 | $273K | Sell |
25,324
-18,983
| -43% | -$173K | ﹤0.01% | 1718 |
|
|
2015
Q3 | $306K | Buy |
44,307
+24,527
| +124% | +$200K | ﹤0.01% | 1676 |
|
|
2015
Q2 | $175K | Buy |
19,780
+7,088
| +56% | +$67K | ﹤0.01% | 1774 |
|
|
2015
Q1 | $125K | Buy |
12,692
+7,692
| +154% | +$96K | ﹤0.01% | 1683 |
|
|
2014
Q4 | $61.3K | Sell |
5,000
-13,204
| -73% | -$161K | ﹤0.01% | 1643 |
|
|
2014
Q3 | $182K | Sell |
18,204
-2,218
| -11% | -$20.6K | ﹤0.01% | 1909 |
|
|
2014
Q2 | $155K | Buy |
+20,422
| New | +$81.5K | ﹤0.01% | 1882 |
|
|
2014
Q1 | – | Sell |
-1,252
| Closed | -$4.16K | – | 3974 |
|
|
2013
Q4 | $4.16K | Sell |
1,252
-25,032
| -95% | -$72.6K | ﹤0.01% | 3223 |
|
|
2013
Q3 | $79.4K | Sell |
26,284
-9,164
| -26% | -$62.8K | ﹤0.01% | 2455 |
|
|
2013
Q2 | $290K | Buy |
+35,448
| New | +$271K | ﹤0.01% | 2030 |
|
BNP Paribas Financial Markets's ACHN Position: Q1 2020 in Review
BNP Paribas Financial Markets sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 19,061 shares — an estimated $115K sold.
BNP Paribas Financial Markets first reported a position in ACHN in Q2 2013 and held it in 25 quarters. The position peaked at $1.14M in Q3 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- BNP Paribas Financial Markets reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- BNP Paribas Financial Markets sold 19,061 Achillion Pharmaceuticals shares in Q1 2020, an estimated $115K.
- BNP Paribas Financial Markets first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 25 quarters.
- BNP Paribas Financial Markets's Achillion Pharmaceuticals position peaked at $1.14M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2020, filed 13 May 2020.